The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK

被引:99
作者
Cooper, C. [2 ,3 ]
Steinbuch, M. [1 ]
Stevenson, R. [1 ]
Miday, R. [1 ]
Watts, N. B. [4 ]
机构
[1] Procter & Gamble Co, Pharmacovigilance & Epidemiol, Mason, OH 45040 USA
[2] Univ Southampton, MRC Epidemiol Resource Ctr, Southampton, Hants, England
[3] Univ Oxford, Inst Musculoskeletal Sci, Oxford, England
[4] Univ Cincinnati, Bone Hlth & Osteoporosis Ctr, Coll Med, Cincinnati, OH 45219 USA
基金
英国医学研究理事会;
关键词
Avascular necrosis; Epidemiology; Osteonecrosis; Risk factors; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AVASCULAR NECROSIS; SYMPTOMATIC OSTEONECROSIS; ORAL CORTICOSTEROIDS; RISK; BISPHOSPHONATES; VALIDATION; JAWS; FRACTURES;
D O I
10.1007/s00198-009-1003-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We conducted a case-control study to examine osteonecrosis (ON) incidence, patient characteristics, and selected potential risk factors using two health record databases in the UK. Statistically significant risk factors for ON included systemic corticosteroid use, hospitalization, referral or specialist visit, bone fracture, any cancer, osteoporosis, connective tissue disease, and osteoarthritis. The purpose of this case-control study was to examine the incidence of osteonecrosis (ON), patient characteristics, and selected potential risk factors for ON using two health record databases in the UK: the General Practice Research Database and The Health Improvement Network. ON cases (n = 792) were identified from 1989 to 2003 and individually matched (age, sex, and medical practice) up to six controls (n = 4,660) with no record of ON. Possible risk factors were considered for inclusion based on a review of published literature. Annual incidence rates were computed, and a multivariable logistic regression model was derived to evaluate selected risk factors. ON of the hip represented the majority of cases (75.9%). Statistically significant risk factors for ON were systemic corticosteroid use in the previous 2 years, hospitalization, referral or specialist visit, bone fracture, any cancer, osteoporosis, connective tissue disease, and osteoarthritis within the past 5 years. Only 4.4% of ON cases were exposed to bisphosphonates within the previous 2 years. This study provides further perspective on the descriptive epidemiology of ON. Studies utilizing more recent data may further elucidate the understanding of ON key predictors.
引用
收藏
页码:569 / 577
页数:9
相关论文
共 22 条
  • [1] Osteonecrosis in patients with SLE
    Abu-Shakra, M
    Buskila, D
    Shoenfeld, Y
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2003, 25 (01) : 13 - 23
  • [2] Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
  • [3] Systemic lupus erythematosus in a multiethnic US cohort (LUMINA):: XXIV.: Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients:: results of a nested matched case-control study
    Calvo-Alen, J.
    McGwin, G.
    Toloza, S.
    Fernandez, M.
    Roseman, J. M.
    Bastian, H. M.
    Cepeda, E. J.
    Gonzalez, E. B.
    Baethge, B. A.
    Fessler, B. J.
    Vila, L. M.
    Reveille, J. D.
    Alarcon, G. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) : 785 - 790
  • [4] Etminan M, 2008, J RHEUMATOL, V35, P691
  • [5] Avascular necrosis following bone marrow transplantation: A case-control study
    Fink, JC
    Leisenring, WM
    Sullivan, KM
    Sherrard, DJ
    Weiss, NS
    [J]. BONE, 1998, 22 (01) : 67 - 71
  • [6] Gladman DD, 2001, J RHEUMATOL, V28, P761
  • [7] Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research
    Lewis, James D.
    Schinnar, Rita
    Bilker, Warren B.
    Wang, Xingmei
    Strom, Brian L.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (04) : 393 - 401
  • [9] MCKOWN K, 2007, OSTEONECROSIS
  • [10] Mok CC, 1998, BRIT J RHEUMATOL, V37, P895